Effects of canagliflozin on brain natriuretic peptide levels in patients with type 2 diabetes on peritoneal dialysis in Japan: protocol for a multicentre, prospective, randomised controlled trial (CARD-PD trial)

What Was Tested

Researchers studied BNP (Nesiritide) in this clinical study publication.

Their study aims to evaluate the impact of SGLT2 inhibitors on cardiovascular disease in individuals with T2D undergoing peritoneal dialysis (PD).

Why It Was Studied

Patients with type 2 diabetes (T2D) undergoing dialysis exhibit a higher mortality rate compared with those with other conditions, primarily due to vascular complications including coronary artery disease, heart failure and stroke.

Nevertheless, the evidence supporting the use of SGLT2 inhibitors in patients undergoing dialysis has been limited.

Who Took Part

The abstract describes 18 participants taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

The CARD-PD study is a multicentre, prospective, randomised, open-label comparison trial of canagliflozin treatment in patients diagnosed with T2D undergoing PD.

The researchers set a target of 18 participants in each group (a total of 36) based on sample size calculations from a previous report.

How the Study Was Run

The researchers set it up as a randomized, open-label, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

Nothing was hidden in this open-label BNP (Nesiritide) study: the participants and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with BNP (Nesiritide) could be set against what happens without it.

Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.

Randomisation is performed using a web-based system, wherein patients are stratified by age, sex and plasma brain natriuretic peptide (BNP) concentrations at the baseline.

What Was Measured

The subject headings attached to it are Canagliflozin, Diabetes Mellitus, Type 2, Japan, Natriuretic Peptide, Brain, Peritoneal Dialysis, Randomized Controlled Trials as Topic and Sodium-Glucose Transporter 2 Inhibitors.

The authors tagged it with the keywords Cardiovascular Disease and Nephrology.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of BNP (Nesiritide) in 18 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (BMJ open), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.